Document is current

Any future updates will be listed below

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy

Crossref DOI link: https://doi.org/10.1007/s12325-021-01757-z

Published Online: 2021-05-08

Published Print: 2021-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark